Scribd Logo
Încărcați

Bine ați venit la Scribd!

  • Drug Study - Bevacizumab

    Încărcat de

    Tarquin Tomada
    689 vizualizări2 pagini
    Bevacizumab (Avastin) is an antineoplastic drug used to treat metastatic colon or rectal cancer. It works by inhibiting vascular endothelial growth factor. It is administered intravenously every 14 days at a dosage of 5 mg/kg. Common adverse reactions include hypertension, proteinuria, bleeding, perforations, and wound healing complications. Notable drug interactions have not been reported. Nursing considerations include monitoring for rare but serious reactions such as reversible posterior leukoencephalopathy syndrome and hypersensitivity during infusion. Treatment should be discontinued for severe adverse reactions.

    Descriere originală:

    Drug Study - Bevacizumab

    Drepturi de autor

    © © All Rights Reserved

    Formate disponibile

    DOCX, PDF, TXT sau citiți online pe Scribd

    Vi se pare util acest document?

    Este necorespunzător acest conținut?

    Raportați acest document
    Bevacizumab (Avastin) is an antineoplastic drug used to treat metastatic colon or rectal cancer. It works by inhibiting vascular endothelial growth factor. It is administered intravenously every 14 days at a dosage of 5 mg/kg. Common adverse reactions include hypertension, proteinuria, bleeding, perforations, and wound healing complications. Notable drug interactions have not been reported. Nursing considerations include monitoring for rare but serious reactions such as reversible posterior leukoencephalopathy syndrome and hypersensitivity during infusion. Treatment should be discontinued for severe adverse reactions.

    Drepturi de autor:

    © All Rights Reserved
    Descărcați ca DOCX, PDF, TXT sau citiți online pe Scribd
    Indicator pentru conținut neadecvat
    689 vizualizări2 pagini

    Drug Study - Bevacizumab

    Încărcat de

    Tarquin Tomada
    Bevacizumab (Avastin) is an antineoplastic drug used to treat metastatic colon or rectal cancer. It works by inhibiting vascular endothelial growth factor. It is administered intravenously every 14 days at a dosage of 5 mg/kg. Common adverse reactions include hypertension, proteinuria, bleeding, perforations, and wound healing complications. Notable drug interactions have not been reported. Nursing considerations include monitoring for rare but serious reactions such as reversible posterior leukoencephalopathy syndrome and hypersensitivity during infusion. Treatment should be discontinued for severe adverse reactions.

    Drepturi de autor:

    © All Rights Reserved
    Descărcați ca DOCX, PDF, TXT sau citiți online pe Scribd
    Indicator pentru conținut neadecvat
    din 2

    Drug Study

    Drug Name
    Generic
    bevacizuma
    b
    Trade
    Avastin

    Classificati
    on
    Antineopla
    stic

    Indications

    Mechanism of Action

    First or second
    line treatment,
    with
    fluorouracilbased
    chemotherapy,
    for metastatic
    colon or rectal
    cancer

    A recombinant
    humanized vascular
    endothelial growth
    factor inhibitor.

    Route/Frequency/Do
    sage
    5 mg/kg IV every 14
    days

    Adverse Reactions

    Drug Interaction

    CNS: asthesia,
    dizziness,
    headache,
    abnormal gait,
    confusion, pain,
    syncope
    CV: intraabdominal
    thrombosis,
    hypertension,
    thromboembolism,
    deep vein
    thrombosis, heart
    failure,
    hypotension
    EENT: epistaxis,
    excess lacrimation,
    gum bleeding,
    taste disorder,
    voice alteration
    GI: anorexia,
    constipation,
    diarrhea,
    dyspepsia,
    flatulence,
    stomatitis,
    vomiting, GI
    hemorrhage,
    abdominal pain,
    colitis, dry mouth,
    nausea
    GU: vaginal
    hemorrhage,

    None reported

    Nursing
    Consideration
    RPLS-associated
    symptoms may
    occur 16 hours to 1
    year after starting
    the drug. It can only
    be confirmed via
    MRI.
    Hypersensitivity
    reactions may occur
    during infusion.
    Stop drug for patients
    developing
    nephrotic
    syndrome, severe
    hypertension,
    hypertensive crisis,
    serious bleeding, GI
    perforation, or
    wound dehiscence.

    proteinuria,
    urinary urgency
    Hematologic:
    leukopenia,
    neutropenia,
    thrombocytopenia
    Metabolic:
    hypokalemia,
    weight loss,
    bilirubinemia
    Musculoskeletal:
    back pain, myalgia
    Respiratory:
    hemoptysis,
    dyspnea, upper
    respiratory tract
    infection
    Skin: alopecia,
    dermatitis,
    discoloration, dry
    skin, exfoliative
    dermatitis, nail
    disorder, skin ulcer

    S-ar putea să vă placă și